Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium

NCT00456924 is registered in ClinicalTrials.gov with HRA Pharma as lead sponsor.

NCT NCT00456924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00456924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium
Lead sponsor
HRA Pharma
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
December 31, 2004
Enrollment
48
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

contraception, gynecologic diseases